ALCAM and colorectal cancer: The combination of CD166/CD44 was previously used to identify CSCs from colorectal cancer cell lines; CD166+/CD44+ cells were found to have higher clonogenicity and accelerated tumour development compared to CD166−/CD44− cells, and the observation was cell dependent [33].